Nanna Therapeutics

Nanna Therapeutics is developing breakthrough drugs for age-related diseases, initially focusing on conditions associated with mitochondrial dysfunction, including Parkinson's disease and amyotrophic lateral sclerosis (ALS). To achieve this, Nanna Therapeutics has established a unique, game-changing platform capable of creating millions of new compounds and functionally screening them at the nanoscale across various assays, including those assessing drug-like properties and toxicity. The platform integrates vast datasets generated using machine learning to select the most effective and safest drug molecules. This approach represents a paradigm shift in the speed, efficiency, and quality of drug discovery while significantly enhancing safety evaluations, aiming to improve clinical success rates. Nanna Therapeutics also collaborates with strategic partners to develop novel first-in-class drugs across all therapeutic areas.